2-Arylbenzoxazoles as CETP inhibitors: Raising HDL-C in cynoCETP transgenic mice

Autor: Kallashi, Florida, Kim, Dooseop, Kowalchick, Jennifer, Park, You Jung, Hunt, Julianne A., Ali, Amjad, Smith, Cameron J., Hammond, Milton L., Pivnichny, James V., Tong, Xinchun, Xu, Suoyu S., Anderson, Matt S., Chen, Ying, Eveland, Suzanne S., Guo, Qiu, Hyland, Sheryl A., Milot, Denise P., Cumiskey, Anne-Marie, Latham, Melanie, Peterson, Laurence B., Rosa, Raymond, Sparrow, Carl P., Wright, Samuel D., Sinclair, Peter J.

Publikováno v: In Bioorganic & Medicinal Chemistry Letters 1 January 2011 21(1):558-561

Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: Close analogs of JANUVIA™ (sitagliptin phosphate)

Autor: Kim, Dooseop, Kowalchick, Jennifer E., Edmondson, Scott D., Mastracchio, Anthony, Xu, Jinyou, Eiermann, George J., Leiting, Barbara, Wu, Joseph K., Pryor, KellyAnn D., Patel, Reshma A., He, Huaibing, Lyons, Kathryn A., Thornberry, Nancy A., Weber, Ann E.

Publikováno v: In Bioorganic & Medicinal Chemistry Letters 2007 17(12):3373-3377

Cyclization of unsaturated amides with triflic anhydride and samarium diiodide

Autor: McDonald, Chriss E ^*, Galka, Amy M, Green, Ahren I, Keane, Joseph M, Kowalchick, Jennifer E, Micklitsch, Christopher M, Wisnoski, David D

Publikováno v: In Tetrahedron Letters 2001 42(2):163-166

(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

Autor: Kim D; Department of Medicinal Chemistry, Merck Research Laboratories, Merck & Co., Inc., Rahway, New Jersey 07065, USA. dooseop_kim@merck.com, Wang L, Beconi M, Eiermann GJ, Fisher MH, He H, Hickey GJ, Kowalchick JE, Leiting B, Lyons K, Marsilio F, McCann ME, Patel RA, Petrov A, Scapin G, Patel SB, Roy RS, Wu JK, Wyvratt MJ, Zhang BB, Zhu L, Thornberry NA, Weber AE

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2005 Jan 13; Vol. 48 (1), pp. 141-51.